Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pediatric Hematology/Oncology
•
Medical Oncology
•
Hematology
Would you consider bone marrow transplant in a pediatric patient with recurrent HLH with no identified exogenous trigger or HLH-associated mutation?
Related Questions
Do you use direct oral anticoagulants to treat port-a-cath related VTE in patients with an active malignancy?
Can defibrotide be given safely for VOD in patients with refractory thrombocytopenia to platelet transfusions?
What is your standard diagnostic workup to confirm GVHD in a patient post-BMT with skin rash and jaundice?
What are the treatment options for relapsed T-ALL in a patient who was nonadherent with AALL and hyper-CVAD regimens?
How do different inflammatory markers like CRP and ferritin contribute differently, if at all, to the monitoring of CART neurotoxicity?
In pure red cell aplasia, does peripheral blood-positive IgG for parvovirus have significance if persistently positive on retesting, but IgM and PCR are negative?
Given the data from SWOG 1826 suggesting that Nivo-AVD is likely the preferred regimen for advanced Hodgkin lymphoma patients, are there scenarios where alternative regimens may still be preferred?
How would you treat suspected secondary HLH in patients whom etoposide is contraindicated?
How do you counsel sickle cell patients on the use of G-CSF to treat neutropenia from other causes, like malignancy?
How would you approach adjusting nivo+AVD therapy for advanced Hodgkin lymphoma if a patient develops treatment limited immunotherapy toxicity?
